ASH 2024 Review: Key Updates in Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

M. Gallogly

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

ASH 2025 Review: Updates in Frontline & R/R DLBCL

University of Colorado Division of Hematology

M. Kamdar

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin I…

2024 ASH Annual Meeting Insights Hub

A. LaCasce

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

ASH & ISHL 2024 Summary: Key Clinical Questions & Highlights in cHL

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

FDA Approval of Acalabrutinib + BR for 1L MCL: Ph3 ECHO Trial & Subg…

Chan Cheah

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

Tafasitamab + Lenalidomide in R/R DLBCL: Updated Results From the L-…

David Bond